Ametek

Bullish Outlook for AMETEK After Earnings Report

阿美特克

Ametek: DA Davidson keeps Buy rating, raises PT to $265 from $240.

Ametek's 15min chart triggers MACD Death Cross, Bollinger Bands Narrowing.

AMETEK Reports Record Q4 Sales, Orders, and Backlog, Expects Mid-to-High Single-Digit Sales Growth in 2026

Ametek: DA Davidson Reiterates Buy Rating, PT Raised to $240

Catalyst<ul> <li>Most analysts rate AME Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough.</li> <li>Long short signals are relatively balanced and it is suggested to pay close attention to market changes.</li></ul>

Key Factors

Ametek (AME) reported fiscal 2025 Q4 earnings on Feb 3, 2026, with both revenue and EPS exceeding expectations and raised 2026 guidance. AME recorded record Q4 sales of $2.0 billion and a backlog of $3.58 billion, with management projecting mid-to-high single-digit sales growth in 2026. AME acquired LKC Technologies to expand its ophthalmic diagnostics offerings, aligning with its acquisition-driven growth strategy in medical technology. DA Davidson reiterated a Buy rating for AME and raised its price target to $265, while KeyBanc and Barclays also adjusted ratings and targets.

AME News